To include your compound in the COVID-19 Resource Center, submit it here.

Sanofi reports alemtuzumab data

Sanofi (Euronext:SAN; NYSE:SNY) said alemtuzumab met one co-primary endpoint but missed the other in the Phase III CARE-MS I trial to treat relapsing-remitting

Read the full 233 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE